增强肝纤维化试验无创诊断NAFLD纤维化的系统评价与荟萃分析
该研究系统评价了增强肝纤维化试验(ELF)对照肝活检诊断非酒精性脂肪性肝病(NAFLD)患者纤维化的准确性。纳入11项报告进展性纤维化和5项报告显著纤维化的研究,采用多阈值随机效应模型进行荟萃分析。结果显示ELF在低阈值(7.7)时排除纤维化敏感性>0.90,但高阈值时仅在患病率>50%的设置中特异度和阳性预测值>0.80;达到特异度0.90需更高阈值(进展性纤维化10.18,敏感性0.57;显著纤维化9.86,敏感性0.55)。结论认为ELF高敏感性但低阈值时特异度有限,高阈值诊断性能在低患病率环境中更受限,临床应结合实践设置患病率选择合适阈值。
要点
- ELF试验在阈值7.7时排除进展性纤维化敏感性>0.90。
- 高阈值下仅患病率>50%时特异度和阳性预测值>0.80。
- 达到特异度0.90需阈值10.18(进展性)或9.86(显著),敏感性仅0.57和0.55。
核心结论
- ELF试验在低截断值时显示高敏感性但特异度有限,可用于排除进展性和显著纤维化。
- 高阈值下诊断性能在低患病率设置中更受限,临床应结合实践患病率选择合适阈值。
研究设计与样本
- 系统评价与荟萃分析,检索MEDLINE、Embase、Web of Science和Cochrane Library。
- 纳入同时使用肝活检(参考标准)和ELF试验的NAFLD患者研究。
- 纳入11项报告进展性纤维化和5项报告显著纤维化的研究,采用多阈值随机效应模型(diagmeta R包)进行荟萃分析。
主要发现
- 阈值7.7时排除纤维化敏感性>0.90。
- 高阈值下仅患病率>50%的设置中特异度和阳性预测值>0.80。
- 达到特异度0.90需阈值10.18(进展性纤维化,敏感性0.57)和9.86(显著纤维化,敏感性0.55)。
关键数值与推荐
- 排除纤维化阈值7.7,敏感性>0.90。
- 特异度0.90对应阈值:进展性纤维化10.18(敏感性0.57),显著纤维化9.86(敏感性0.55)。
- 高阈值下特异度和阳性预测值>0.80仅见于患病率>50%的设置。
临床怎么用
- 临床应仔细考虑实践设置中的可能疾病患病率,并采用合适阈值以达到期望性能。
- 在低患病率设置(如初级保健)中,ELF高阴性预测值可用于排除进展性纤维化。
- 低患病率时ELF阳性预测值低,可能需要额外策略进行阳性诊断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The enhanced liver fibrosis (ELF) test has been proposed for the non-invasive assessment of advanced fibrosis in patients with non-alcoholic fatty liver disease (NAFLD). We performed a systematic review to estimate the accuracy of this test against biopsy. METHODS: In this systematic review, we searched MEDLINE, Embase, Web of Science and the Cochrane Library for studies that included patients with NAFLD and that used both liver biopsy (as the reference standard) and the ELF test. Two authors independently screened the references, extracted the data and assessed the quality of included studies. Due to the variation in reported thresholds, we used a multiple thresholds random effects model for meta-analysis (diagmeta R-package). RESULTS: The meta-analysis of 11 studies reporting advanced fibrosis and 5 studies reporting significant fibrosis showed that the ELF test had a sensitivity of >0.90 for excluding fibrosis at a threshold of 7.7. However, as a diagnostic test at high thresholds, the test only achieved specificity and positive predictive value >0.80 in very high prevalence settings (>50%). To achieve a specificity of 0.90 for advanced and significant fibrosis, thresholds of 10.18 (sensitivity: 0.57) and 9.86 (sensitivity: 0.55) were required, respectively. CONCLUSION: The ELF test showed high sensitivity but limited specificity to exclude advanced and significant fibrosis at low cut-offs. The diagnostic performance of the test at higher thresholds was found to be more limited in low-prevalence settings. We conclude that clinicians should carefully consider the likely disease prevalence in their practice setting and adopt suitable test thresholds to achieve the desired performance. LAY SUMMARY: The enhanced liver fibrosis test has been suggested as a non-invasive blood test to aid the diagnosis of severe liver fibrosis in patients with non-alcoholic fatty liver disease (NAFLD). Our study results showed that the test has a high negative predictive value, especially in populations with low disease prevalence (likely encountered in primary care); so, it can exclude advanced fibrosis in patients with NAFLD. However, when prevalence is low, the positive predictive value of the enhanced liver fibrosis test is low, suggesting that additional strategies may be needed to make a positive diagnosis in such settings.
引用
- Vali Y, Lee J, Boursier J, et al. Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis. J Hepatol. 2020. PMID: 32275982. doi:10.1016/j.jhep.2020.03.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。